Multicenter evaluation of six methods for predicting warfarin maintenance-dose requirements from initial response. 1985

W T Sawyer, and T E Poe, and B R Canaday, and J S Weiner, and D M Williams, and C E Webb, and M J Ellison

Warfarin maintenance-dose requirements predicted by six mathematical methods based on initial response to therapy were compared with patients' actual dose requirements in a multicenter trial. Data were collected for patients who had received an initial regimen of warfarin sodium 10 mg orally every 24 hours for three days and for whom a prothrombin time (PT) had been determined 16-20 hours after the third dose. Patients' individual dose requirements and PT values were recorded during one to three follow-up visits after discharge from one of seven medical centers. Prothrombin ratios (patient PT divided by control PT) calculated on day 4 were used for maintenance-dose prediction by five methods; a sixth method was based on the cumulative warfarin dose-PT response curve up to a PT value of 20 seconds. For 54 men and 30 women who qualified for the study, 197 maintenance-dose-PT response measurements were recorded; 95 in the first four weeks of therapy, 76 during weeks 5-12, and 26 at 6-12 months after initial treatment. Prothrombin ratios were within the therapeutic range (PT 1.5-2.5 times the control value) in 154 observations, and the mean actual warfarin sodium maintenance dose associated with therapeutic response was 7.6 mg/day. For patients with therapeutic prothrombin ratios, dose predictions by the five methods using prothrombin ratios (PRs) correlated significantly with actual dose requirements. The formula that predicted doses numerically closest to the actual dose is as follows: Dose = 11.17 - 21.08 (log PR). Only 45 observations were obtained for the sixth prediction method, and the correlation between actual and predicted doses was not significant. Initial warfarin maintenance-dose requirements can be predicted effectively based on one PT determination after administration of three daily 10-mg doses.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007902 Length of Stay The period of confinement of a patient to a hospital or other health facility. Hospital Stay,Hospital Stays,Stay Length,Stay Lengths,Stay, Hospital,Stays, Hospital
D008297 Male Males
D008722 Methods A series of steps taken in order to conduct research. Techniques,Methodological Studies,Methodological Study,Procedures,Studies, Methodological,Study, Methodological,Method,Procedure,Technique
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011655 Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS. Pulmonary Thromboembolism,Thromboembolism, Pulmonary,Embolism, Pulmonary,Embolisms, Pulmonary,Pulmonary Embolisms,Pulmonary Thromboembolisms,Thromboembolisms, Pulmonary
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003365 Costs and Cost Analysis Absolute, comparative, or differential costs pertaining to services, institutions, resources, etc., or the analysis and study of these costs. Affordability,Analysis, Cost,Cost,Cost Analysis,Cost Comparison,Cost Measures,Cost-Minimization Analysis,Costs and Cost Analyses,Costs, Cost Analysis,Pricing,Affordabilities,Analyses, Cost,Analyses, Cost-Minimization,Analysis, Cost-Minimization,Comparison, Cost,Comparisons, Cost,Cost Analyses,Cost Comparisons,Cost Measure,Cost Minimization Analysis,Cost, Cost Analysis,Cost-Minimization Analyses,Costs,Measure, Cost,Measures, Cost
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females

Related Publications

W T Sawyer, and T E Poe, and B R Canaday, and J S Weiner, and D M Williams, and C E Webb, and M J Ellison
August 2015, Therapeutic drug monitoring,
W T Sawyer, and T E Poe, and B R Canaday, and J S Weiner, and D M Williams, and C E Webb, and M J Ellison
October 1979, American journal of hospital pharmacy,
W T Sawyer, and T E Poe, and B R Canaday, and J S Weiner, and D M Williams, and C E Webb, and M J Ellison
January 1984, Clinical pharmacy,
W T Sawyer, and T E Poe, and B R Canaday, and J S Weiner, and D M Williams, and C E Webb, and M J Ellison
June 1991, Australian and New Zealand journal of medicine,
W T Sawyer, and T E Poe, and B R Canaday, and J S Weiner, and D M Williams, and C E Webb, and M J Ellison
January 1983, Drug intelligence & clinical pharmacy,
W T Sawyer, and T E Poe, and B R Canaday, and J S Weiner, and D M Williams, and C E Webb, and M J Ellison
August 1985, British journal of clinical pharmacology,
W T Sawyer, and T E Poe, and B R Canaday, and J S Weiner, and D M Williams, and C E Webb, and M J Ellison
April 1979, American journal of surgery,
W T Sawyer, and T E Poe, and B R Canaday, and J S Weiner, and D M Williams, and C E Webb, and M J Ellison
March 1979, Lancet (London, England),
W T Sawyer, and T E Poe, and B R Canaday, and J S Weiner, and D M Williams, and C E Webb, and M J Ellison
April 1979, Lancet (London, England),
W T Sawyer, and T E Poe, and B R Canaday, and J S Weiner, and D M Williams, and C E Webb, and M J Ellison
March 1979, Lancet (London, England),
Copied contents to your clipboard!